Monoamine oxidase: Difference between revisions
imported>Robert Badgett (New page: In biology, '''monoamine oxidase''' is "an enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in ...) |
imported>Meg Taylor No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[biology]], '''monoamine oxidase''' is "an [[enzyme]] that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of [[catecholamine]]s and [[serotonin]] in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.<ref>{{MeSH}}</ref> | In [[biology]], '''monoamine oxidase''' is "an [[enzyme]] that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of [[catecholamine]]s and [[serotonin]] in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.<ref>{{MeSH}}</ref> | ||
| Line 11: | Line 12: | ||
[[Monoamine oxidase inhibitor]]s are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."<ref>{{MeSH|Monoamine oxidase inhibitors}}</ref> Reversible inhibitor of monoamine oxidase A (RIMA) | [[Monoamine oxidase inhibitor]]s are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."<ref>{{MeSH|Monoamine oxidase inhibitors}}</ref> Reversible inhibitor of monoamine oxidase A (RIMA) | ||
[[Clorgyline]] | [[Clorgyline]] selectively inhibits MAO-A.<ref name="isbn0-07-145153-6"/> | ||
[[Deprenyl]] | [[Deprenyl]] selectively inhibits MAO-B.<ref name="isbn0-07-145153-6"/> [[Rasagiline]], used to treat [[Parkinson's disease]], is an inhibitor of Type B monoamine oxidase.<ref>N Engl J Med 2009; 361:1268-1278, Sep 24, 2009. PMID 19776408</ref> | ||
==References== | ==References== | ||
{{reflist}} | |||
Latest revision as of 11:24, 2 October 2013
In biology, monoamine oxidase is "an enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.[1]
Classification
Type A monoamine oxidase (MAO-A)
MAO-A deaminates norepinephrine and serotonin.[2]
Type B monoamine oxidase (MAO-B)
MAO-B deminates phenylethylamines.[2]
Pharmacology
Monoamine oxidase inhibitors are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."[3] Reversible inhibitor of monoamine oxidase A (RIMA)
Clorgyline selectively inhibits MAO-A.[2]
Deprenyl selectively inhibits MAO-B.[2] Rasagiline, used to treat Parkinson's disease, is an inhibitor of Type B monoamine oxidase.[4]
References
- ↑ Anonymous (2024), Monoamine oxidase (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 2.2 2.3 Katzung, Bertram G. (2006). “30. Antidepressant agents”, Basic and Clinical Pharmacology, 10th. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6.
- ↑ Anonymous (2024), Monoamine oxidase inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ N Engl J Med 2009; 361:1268-1278, Sep 24, 2009. PMID 19776408